Abstract: Provided is a method for training a tone conversion model. The method includes: acquiring a sample set; acquiring a first tone feature of any piece of the sample audio data sample audio data by a tone extraction network in an original tone conversion model; acquiring a first semantic feature based on the first tone feature and a linear spectrum corresponding to the sample audio data by a tone removal network in the original tone conversion model; and acquiring synthesized audio data based on the first semantic feature and a second tone feature of the target audio data corresponding to the sample audio data by a vocoder in the original tone conversion model; and acquiring a trained tone conversion model by training the original tone conversion model based on the target audio data and synthesized audio data corresponding to each piece of the sample audio data.

Abstract: A method for constructing cartoonization models is provided. The method includes: generating a predetermined number of sample authentic images using a pre-trained first generative model; constructing a second generative model based on the first generative model, and generating a sample cartoon image corresponding to each of the sample authentic images using the second generative model; acquiring a sample image pair by combining the each of the sample authentic images with the corresponding sample cartoon image; and generating a cartoonization model for converting a target image into a fully cartoonized image by fitting, based on a sample set consisting of multiple sample image pairs, a predetermined initial cartoonization model with a weight corresponding to the second generative model as an initial weight.

Abstract: An electrochromic apparatus includes a first glass, a first adhesive layer disposed on the first glass, a second glass, a second adhesive layer disposed on the second glass, a solid-state electrochromic device (ECD) interposed between the first adhesive layer and the second adhesive layer, and a sealant disposed at edges of the first glass and the second glass to seal the ECD. The first adhesive layer and the second adhesive layer are disposed between the first glass and the second glass. The first adhesive layer and the second adhesive layer are optically transparent. Edges of the adhesive layers are flush with or beyond edges of the ECD. The sealant is adhesive and waterproof.

Abstract: Provided is a method for training an image generation model, including: acquiring a first transformation model by training; acquiring a reconstruction model by training based on the first transformation model; acquiring a second transformation model by training; generating a grafted transformation model by grafting the first transformation model with the second transformation model; and generating the image generation model based on the reconstruction model and the grafted transformation model. The first transformation model is configured to generate a first training image according to a first noise sample. The first training image is an image of a first style. The reconstruction model is configured to map an original image sample to a latent variable corresponding to the original image sample. The second transformation model is configured to generate a second training image according to a second noise sample. The second training image is an image of a second style.

Abstract: A key frame scheduling method and apparatus include: performing feature extraction on a current frame through a first network layer of a neural network to obtain low-layer features of the current frame acquiring a scheduling probability of the current frame according to low-level features of a previous key frame adjacent to the current frame and the low-level features of the current frame; determining whether the current frame is scheduled as a key frame according to the scheduling probability value of the current frame; and when determining that the current frame is scheduled as a key frame, performing feature extraction on low-level features of a current key frame via a second network layer of the neural network to obtain high-level features of the current key frame, where the network depth of the first network layer is less than the network depth of the second network layer.

Abstract: An electrochromic device includes a first flexible substrate, a first transparent electrode disposed on the first flexible substrate, an electrochromic layer disposed on the first transparent electrode, and a solid electrolyte layer disposed on the electrochromic layer. The solid electrolyte layer contains less than 20 wt % of neutral small organic molecules having a molecular weight of 3000 or less. The electrochromic device further includes an ion storage layer disposed on the solid electrolyte layer, a second transparent electrode disposed on the ion storage layer, and a second flexible substrate disposed on the second transparent electrode.

Abstract: An electrochromic apparatus includes a first glass, a first adhesive layer disposed on the first glass, a second glass, a second adhesive layer disposed on the second glass, a solid-state electrochromic device (ECD) interposed between the first adhesive layer and the second adhesive layer, and a sealant disposed at edges of the first glass and the second glass to seal the ECD. The first adhesive layer and the second adhesive layer are disposed between the first glass and the second glass. The first adhesive layer and the second adhesive layer are optically transparent. Edges of the adhesive layers are flush with or beyond edges of the ECD. The sealant is adhesive and waterproof.

Abstract: A key frame scheduling method and apparatus include: performing feature extraction on a current frame through a first network layer of a neural network to obtain low-layer features of the current frame acquiring a scheduling probability of the current frame according to low-level features of a previous key frame adjacent to the current frame and the low-level features of the current frame; determining whether the current frame is scheduled as a key frame according to the scheduling probability value of the current frame; and when determining that the current frame is scheduled as a key frame, performing feature extraction on low-level features of a current key frame via a second network layer of the neural network to obtain high-level features of the current key frame, where the network depth of the first network layer is less than the network depth of the second network layer.

Abstract: An electrochromic device includes a first flexible substrate, a first transparent electrode disposed on the first flexible substrate, an electrochromic layer disposed on the first transparent electrode, and a solid electrolyte layer disposed on the electrochromic layer. The solid electrolyte layer contains less than 20 wt % of neutral small organic molecules having a molecular weight of 3000 or less. The electrochromic device further includes an ion storage layer disposed on the solid electrolyte layer, a second transparent electrode disposed on the ion storage layer, and a second flexible substrate disposed on the second transparent electrode.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: Adipose tissue has proven to serve as an abundant, accessible, and rich source of endothelial or vascular endothelial cells suitable for tissue engineering. We describe a detailed method for the isolation and purification of endothelial cells using purified enzymes and antibody-based selection. The cells can be obtained from liposuction procedures and used in vascular grafts.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: The present invention provides compositions comprising isolated elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: Adipose tissue has proven to serve as an abundant, accessible, and rich source of endothelial or vascular endothelial cells suitable for tissue engineering. We describe a detailed method for the isolation and purification of endothelial cells using purified enzymes and antibody-based selection. The cells can be obtained from liposuction procedures and used in vascular grafts.

Abstract: The present invention provides compositions comprising isolated human collagen, isolated human elastin and a pharmaceutically acceptable carrier wherein the human elastin is substantially insoluble in water with a molecular weight greater than 100 kDa. The present invention further provides methods and kits for soft tissue augmentation.

Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.

Abstract: The invention relates to a Neutrokine-alpha protein in crystalline form, a method of preparing a Neutrokine-alpha protein in crystalline form, and methods of using a Neutrokine-alpha protein in crystalline form. In particular, the three-dimensional structure of a Neutrokine-alpha protein in crystalline form is used to design molecules that have biological activity. The methods are useful for designing compounds that bind to a Neutrokine-alpha protein, inhibit a Neutrokine-alpha protein, mimic a Neutrokine-alpha protein, and/or enhance the activity of a Neutrokine-alpha protein. The three-dimensional structure of a Neutrokine-alpha protein, as provided herein, is also used to determine the three-dimensional of other Neutrokine-alpha proteins and homologues thereof.

Abstract: The invention relates to methods of isolating differentiable fetal-derived cells from various tissues of the placenta. Specifically, some of the methods of the present invention relate to isolating differentiable amnion-derived cells, while other methods of the present invention relate to isolating differentiable chorion-derived cells. The present invention also relates to methods of inducing these isolated differentiable amnion-derived and differentiable chorion-derived cells to at least partially differentiate. The present invention also relates to methods of treating insulin deficiencies in a subject by administering these differentiable amnion-derived cells and/or differentiable chorion-derived cells to subjects in need thereof.

Abstract: Human chemokine polypeptides and DNA (RNA) encoding such chemokine polypeptides and a procedure for producing such polypeptides by recombinant techniques is disclosed. Also disclosed are methods for utilizing such chemokine polypeptides for the treatment of leukemia, tumors, chronic infections, autoimmune disease, fibrotic disorders, wound healing and psoriasis. Antagonists against such chemokine polypeptides and their use as a therapeutic to treat rheumatoid arthritis, autoimmune and chronic inflammatory and infective diseases, allergic reactions, prostaglandin-independent fever and bone marrow failure are also disclosed.